Target intelligence / Profile preview

Protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) signaling proteins (PKC/MAPK)

Target
PKC/MAPK
Molecular classification
Enzyme, Serine/threonine protein kinase, Intracellular signaling protein
01

Overview

Protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) signaling proteins are two distinct but highly interconnected families of serine/threonine kinases that mediate vital cellular processes (PMID: 22123811). The PKC family, which includes multiple isoforms like alpha, beta, and delta, is primarily activated by lipid-derived second messengers and calcium to regulate cell polarity, transport, and survival (UniProt P17252). The MAPK signaling cascade, particularly the Raf-MEK-ERK pathway, serves as a central conduit for growth factor signaling, controlling cell proliferation and differentiation (PMID: 17327480). PKC isoforms often act upstream of the MAPK cascade, where they can directly phosphorylate and activate Raf-1, creating a synergistic signaling network (PMID: 10748117). Dysregulation of these pathways is a major driver in various cancers, inflammatory diseases, and cardiovascular disorders, making them significant therapeutic targets (PMID: 28211444). While drugs like midostaurin (targeting PKC) and trametinib (targeting MEK) have been developed, the complexity and crosstalk between these proteins often lead to therapeutic challenges such as drug resistance and off-target toxicities (PMID: 24204714).

Other names
PKC-MAPK pathwayProtein kinase C and MAPK cascadePKC and mitogen-activated protein kinase signaling
02

Mechanism of action

Inhibition of serine/threonine kinase activity to disrupt downstream phosphorylation cascades and modulate gene expression.

03

Biological functions

Signal transductionCell proliferationCell differentiationApoptosisGene expression
04

Disease associations

CancerInflammationCardiovascular diseaseNeurodegenerative diseaseDiabetes
05

Safety considerations

Dermatological toxicityGastrointestinal distressCardiotoxicityOcular toxicityDevelopment of bypass signaling resistance
06

Interacting drugs

Midostaurin

8 more in the full profile.

07

Biomarkers

Phospho-ERK1/2Phospho-PKCp38 MAPK phosphorylationKi-67

Beyond the preview

Go deeper on Protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) signaling proteins (PKC/MAPK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) signaling proteins (PKC/MAPK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call